FDA Expands Use of Approved Breast Cancer Drug : RushPRNews - Newswire & Global Press Release Distribution

 
Bookmark and Share

FDA Expands Use of Approved Breast Cancer Drug

February 1, 2010

Washington D.C. (RPRN) 02/01/10 — Provides oral regime for hormone positive and HER2-positive advanced breast cancer

The U.S. Food and Drug Administration today approved Tykerb (lapatinib) in combination with Femara (letrozole) to treat hormone positive and HER2-positive advanced breast cancer in postmenopausal women for whom hormonal therapy is indicated.

HER2 is a protein involved in normal cell growth. It is found on some types of cancer cells, including breast cancer cells. In hormone positive breast cancer, the presence of certain hormones contributes to breast cancer growth. In HER2-positive breast cancer, stimulation of the HER2 receptor contributes to cancer cell growth. Breast cancer is the second leading cause of death among women. More than 192,000 women will be diagnosed with breast cancer this year.

“This drug combination of Tykerb plus Femara provides women being treated for advanced breast cancer with an important treatment option. This entirely oral treatment regimen works by targeting both HER2 and the hormone receptors, thereby slowing the cancer cells’ ability to grow or spread,” said Richard Pazdur, M.D., director of the Office of Oncology Drug Products, in the FDA’s Center for Drug Evaluation and Research.

Women with HER2-positive disease receiving the Tykerb plus Femara combination more than doubled the time they lived without the cancer progressing compared with those receiving Femara alone (35 weeks vs. 13 weeks). Women in the company sponsored study were randomized to receive Tykerb plus Femara or Femara alone. It is too early to determine whether an improvement in overall survival will be observed in the clinical trial.

Tykerb works by depriving tumor cells of signals needed to grow. Tykerb enters the cell and blocks the function of the HER2 protein.

Tykerb was initially approved in combination with a chemotherapy drug, Xeloda (capecitabine) in 2007. This combination was used to treat women with advanced breast cancer tumors with the HER2 protein who had received prior treatment with chemotherapy drugs, including an anthracycline and a taxane, and Herceptin (trastuzumab), an anti-cancer antibody used to treat HER2-positive advanced breast cancer.

Safety information from this study was consistent with previous Tykerb clinical studies in advanced breast cancer. The most commonly reported side effects of the combination were diarrhea, rash, nausea and fatigue. Treatment with Tykerb also has been associated with decreases in heart function, liver damage, and lung tissue inflammation. Fetal harm may occur if used to treat advanced breast cancer in pregnant women. Patients should talk to their health care provider about the potential side effects, drug interactions, and other medical conditions.

 

Tykerb is marketed by Collegeville, Pa.-based GlaxoSmithKline.
Femara is marketed by Lebanon, Pa.-based Novartis AG.

 

For more information:

 

FDA Office of Oncology Drug Products
http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm091745.htm

 

National Cancer Institute – Breast Cancer
http://www.cancer.gov/cancertopics/types/breast

 

RSS Feed for FDA News Releases [what is RSS?]

About the author:

FDA is an agency within the Department of Health and Human Services and consists of seven centers and offices

Click here to see all news from this author/company

Filed Under: FDA- Pharmaceutical news, Health and Fitness, Food-Nutrition, Lifestyle, PRESS RELEASE

RUSH PR NEWS newswire and press release services at rushprnews.com / Anne Howard annehowardpublicist.com

Content- Legal Responsibility - All material is copyrighted - You may repost but you MUST link back to the original post on your page and acknowledge Rush PR News as the news source. Rush PR News is not legally and/or morally responsible for content of press releases, opinions expressed or fact-checking.

Rush PR News cannot be held legally responsible for material published and distributed through its newswire service or published in its press-room and therefore cannot be sued for published material. Third-party must be contacted directly to dispute content.

Rush PR News is not the contact for material published.

RSSFeed PRESS & SOCIAL MEDIA RELEASES

GeneSegues Therapeutics Awarded Contract For Development of Nanocapsule-based Vaccine for Biodefense Pathogen

MINNEAPOLIS, MN 12/18/14 · Company Collaborating With U.S. Army Researchers on Topically...

Enjoy a Virtual Tour of Canada's Favourite Spa

GRAFTON, ON 12/16/14 · A brand new tour of Ste. Anne's Spa...

Bahama Beach Club Hosts Christmas and 12th New Year’s Eve Party

Treasure cay 12/13/14 · If you're looking for the perfect place to...

Opportunistic Brand Savvy Investors set to snap up Stackcap Patent

London, UK 12/11/14 · Business savvy investors welcomed an exciting opportunity this...

Newborn Foundation Applauds Reauthorization of Newborn Screening Saves Lives Act

WASHINGTON, D.C. 12/11/14 · The U.S. House of Representatives has passed H.R....

SecurifyApp makes it safe to be Home Alone during this holiday season

New York, New Yrok 12/10/14 · More Americans fall victim to accident, theft and...

Routehappy Raises $3.3M in Funding to Expand Airline & Distributor Products

NEW YORK 12/10/14 ·  -- Routehappy, the product differentiation platform for air travel,...

Spa Lovers Select Ste. Anne's as Canada's Top Destination... Again!

GRAFTON, ON 12/04/14 · Spafinder Wellness once again has awarded Ste. Anne's...

Who Couldn`t Use a Hug? Announcing the HugTrain 6th Annual Hug Tour Dec 2014

Montreal, Quebec, Canada 12/03/14 · Cross Continental Canadian-U.S. Train Journey to Raise Spirits...

Zikto announces stretch goals for successful Kickstarter campaign

Los Angeles/Seoul, Korea 12/01/14 · Campaign reaches global audience! Riding high on the accomplishment...

Coffee With Dr. Stewart

Austin, TX 11/25/14 · A brother and sister bring an exciting new...

Arki Kickstarter reaches $100K target in 13 days

Los Angeles/Seoul, Korea 11/24/14 · One step closer to a walking revolution The kickstarter...

Zikto taking award-winning Arki to Startup Nations Summit

Seoul, Korea 11/22/14 · Zikto taking award-winning Arki to Startup Nations Summit The...

The End of Transparency? Don't be a fraud target

Carrollton, TX 11/18/14 · - Over the years, progressive and productive societies...